Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05421832 · ClinicalTrials.gov registry record
A Novel Measurement Concept to Objectively Quantify Severity of Vocal and Speech Related Symptoms Associated With Parkinson's Disease
A clinical trial, sponsored by Northwestern University.
- Completed
- Registry status
- 91
- Enrollment target
NCT05421832: Completed study, sponsored by Northwestern University.
NCT05421832 is a clinical trial that has completed, run by Northwestern University. The registered enrollment target is 91 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05421832 has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 91 participants
- Enrollment target
Study Summary
The aim of this research program is to develop and validate a smartphone app-based digital measurement concept that: * Objectively quantifies the severity of Parkinson's Disease (PD) related vocal and speech symptoms; * Accurately and sensitively identifies vocal and speech abnormalities associated with the prodromal stage of PD.
Primary Outcome
o % Interpretable minutes of data per patient
Interventions
- DEVICE Digital Speech Application
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2022-09-27 |
| Est. Completion | 2025-06-30 |
What the finished NCT05421832 record still lists
NCT05421832 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 91 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Digital Speech Application is the first listed.
NCT05421832 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05421832 about?
NCT05421832 is a clinical study titled "A Novel Measurement Concept to Objectively Quantify Severity of Vocal and Speech Related Symptoms Associated With Parkinson's Disease". The aim of this research program is to develop and validate a smartphone app-based digital measurement concept that: * Objectively quantifies the severity of Parkinson's Disease (PD) related vocal and speech symptoms; * Accurately and sensitively identifies vocal and speech abnormalities associated...
What is the current status of trial NCT05421832?
This trial is currently completed. The enrollment target is 91 participants. The study started on 2022-09-27. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT05421832?
The interventions under investigation include: Digital Speech Application (DEVICE).
Who is sponsoring clinical trial NCT05421832?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI